Walkable neighborhoods associated with lower risk of some cancers – study
Denser neighborhoods with more amenities associated with lower rates of obesity-related cancers in womenLiving in more walkable neighborhoods can lower the rate of obesity-related cancers in women, a newstudy has found.Living in a densely populated neighborhood with accessible amenities such as grocery stores and small businesses promotes walking, and women living in more walkable neighborhoods had a lower risk of at least five types of cancer, including postmenopausal breast, ovarian, pancreatic and colorectal cancers, as well as multiple myeloma.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 5, 2023 Category: Science Authors: Aliya Uteuova Tags: Medical research Cancer Cities US news Health Source Type: news
IVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA Therapy
THURSDAY, Oct. 5, 2023 -- Many patients with multiple myeloma treated with anti-B cell maturation antigen (BCMA) therapy have infections, and the rate of infections is significantly lower when patients are receiving intravenous immunoglobulin,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2023 Category: Pharmaceuticals Source Type: news
Diabetes Could Speed Progression of Blood Cancer Myeloma
MONDAY, Oct. 2, 2023 -- Diabetes may accelerate the growth of a blood cancer known as multiple myeloma, affecting overall survival, according to a new study.
The research, published Sept. 29 in the journal Blood Advances, also underscores... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 2, 2023 Category: General Medicine Source Type: news
IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myeloma
(MedPage Today) -- Use of intravenous immunoglobulin (IVIg) may substantially reduce the risk for severe infections in multiple myeloma patients treated with an anti-B-cell maturation antigen (BCMA) bispecific antibody, a small retrospective study... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2023 Category: Hematology Source Type: news
Racial and Ethnic Disparities in RRMM
Learn more about how racial and ethnic disparities affect relapsed/refractory multiple myeloma (RRMM) outcomes. (Source: WebMD Health)
Source: WebMD Health - September 29, 2023 Category: Consumer Health News Source Type: news
Newest Treatments for RRMM
The latest advances in treatments for relapsed/refractory multiple myeloma (RRMM) include medicines that better target myeloma cells. Learn more. (Source: WebMD Health)
Source: WebMD Health - September 29, 2023 Category: Consumer Health News Source Type: news
NHS spending watchdog U-turns decision to pull funding from vital bone marrow treatment drug
Some 6,000 people in England contract multiple myeloma each year which cannot currently be cured. It can hit several areas of the body at once, such as the spine, skull, pelvis and ribs. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2023 Category: Consumer Health News Source Type: news
Debate: Should Smoldering Myeloma Be Treated? Debate: Should Smoldering Myeloma Be Treated?
The two experts based their arguments largely on the same two studies, the only randomized trials to tackle the issue to date.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
No. 2 House Republican Steve Scalise returns to the Capitol after his blood cancer diagnosis
Rep. Steve Scalise has returned to the U.S. Capitol for the first time since being diagnosed with a blood cancer known as multiple myeloma (Source: ABC News: Health)
Source: ABC News: Health - September 14, 2023 Category: Consumer Health News Tags: Health Source Type: news
Caring for Someone With RRMM
Learn more about relapsed/refractory multiple myeloma (RRMM) and how you can offer the best support possible for a loved one with RRMM. (Source: WebMD Health)
Source: WebMD Health - September 12, 2023 Category: Consumer Health News Source Type: news
2seventy bio cutting 176 jobs, search for new chief executive
2seventy bio Inc. stock TSVT, rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it’s cutting 176 jobs or 40% of its work force and launching a search for a new chief executive. Current chief executive Nick Leschly will become chairman of the…#bioinc #tsvt #nickleschly #jwtherapeutics2126 #myeloma (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2023 Category: Consumer Health News Source Type: news
FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma
The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 11, 2023 Category: Transplant Surgery Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Aphexda (motixafortide) to Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
Aphexda is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade
One dosage of Aphexda plus filgrastim enabled a majority of patients to achieve the collection goal of≥ 6 million... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 11, 2023 Category: Drugs & Pharmacology Source Type: news
Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma
(MedPage Today) -- The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on Monday.
Recent advances in... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - September 11, 2023 Category: Surgery Source Type: news
Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma
(MedPage Today) -- A novel protein-degrading agent exhibited promising activity in patients with relapsed/refractory multiple myeloma, results of a preliminary clinical trial showed.
Among 101 patients who received the recommended phase II dose... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 30, 2023 Category: Hematology Source Type: news
